Skip to main content
NSP $52.20 -2.92%
NSP logo

NSP · Insperity, Inc.

Track NSP — free
$52.20 -1.57 (-2.92%) At close · Aug 14
Market Cap
$1.92B
Shares
38.20M
All earnings calls

Earnings call · FY2025 Q4

Insperity, Inc. Q4 FY2025 Earnings Call

Insperity, Inc. Q4 FY2025 Earnings Call

Concluded Feb 10, 2026 Audio replay
Feb 10, 2026 55:28 43 turns
Period
FY2025 Q4
Runtime
55:28
Sources
4 artifacts

Executive readout · one minute

What matters this quarter

Insperity reported a Q4 2025 net loss of $33 million and adjusted EBITDA of negative $13 million due to elevated benefits costs, though it achieved its year-end gross profit margin recovery objective and projects a significant profitability recovery in 2026.

Worksite employee growth guidance 77 Margin and profit recovery 45 HRScale and Workday partnership 39 Three-year plan and 40th anniversary 12 Organization realignment and cost actions 11 Client retention and pricing actions 9

Management tone

Cautious

Net tone -15 · moderate hedging

Grounding quotes
  • “We accomplished this key objective. As we enter 2026, we have seen a step-up in several key drivers of gross profit margin that we believe position us for a significant recovery in profitability this year.”
  • “we also made a difficult but necessary decision to rightsize our organization to the current and future needs of the company”
  • “the labor market continued to reflect uncertainty in the small- and medium-sized business community at large and within our client base at Insperity”
  • “At this point, we expect growth for the year between minus 1.5% to plus 1.5% compared to 2025.”

Forward guidance

11 guided metrics

Management's latest ranges and targets are included below.

Research coverage

4 live sources

Switch sources without leaving this page or losing your listening position.

Revenue · derived Q4 $1.67B +3.4% YoY
Gross margin · derived Q4 10.3% -3.2 pp YoY
Net income · derived Q4 -$33.00M

Research materials

Open the source you need; every reader stays inside this workspace.

Key takeaways

What improved, and what deserves a closer read.

Constructive signals

  • Completed year-end transition with a step-up in gross profit margin, positioning the company for significant profitability recovery in 2026
  • Amended credit facility extended maturity to Dec 15, 2028, increased capacity from $650M to $750M, raised leverage ratio to 3.75x, leaving $380M of available capacity
  • Retention rate of approximately 83% in 2025, an improvement over the prior year's ~81%
  • Operating expenses decreased 6% year-over-year in Q4 2025
  • Full year 2025 adjusted EBITDA of $131 million and adjusted EPS of $1.03, with $109M returned to shareholders through buybacks and dividends
  • HRScale rollout underway, with expected meaningful revenue beginning in 2027

Risks & pressure points

  • Q4 2025 net loss of $33 million, diluted EPS of $(0.88), adjusted EPS of $(0.60), and adjusted EBITDA of $(13) million
  • Gross profit decreased 21% year-over-year in Q4 2025 to $172 million due to elevated benefits costs from inpatient, outpatient, pharmacy trends, and large claim activity
  • Full-year 2025 net loss of $7 million and diluted EPS of $(0.19) amid continued SMB employment stagnation and industry-wide health care claim cost step-ups
  • Worksite employee growth guidance for 2026 of minus 1.5% to plus 1.5%, lowered by about 3% due to fewer-than-expected paid WSEEs entering the year
  • Realignment Plan eliminating approximately 4% of non-sales positions with estimated one-time charges of approximately $9 million, majority to be incurred in Q1 2026
  • Elevated health care claim costs expected to continue at an elevated level in 2026, with only ~2% cost reduction expected from new UnitedHealthcare contract and plan design changes

Key moments

Jump directly to management's words in the synchronized transcript.

Forward guidance

From the 8-K filed Feb 10, 2026.

Metric Guided
Adjusted EPS
Q1 2026
$1.03 – $1.50
Adjusted EPS
Full Year 2026
$1.69 – $2.72
Net income table
Q1 2026
$22M – $40M
Net income table
Full Year 2026
$18M – $57M
EBITDA table
Q1 2026
$58M – $88M
EBITDA table
Full Year 2026
$108M – $168M
Adjusted EBITDA table
Q1 2026
$81M – $111M
Diluted EPS table
Full Year 2026
$0.47 – $1.50
Diluted EPS table
Q1 2026
$0.57 – $1.04
Adjusted EBITDA table
Full Year 2026
$170M – $230M

Guidance from the call

Stated verbally and extracted from the transcript.

Metric Guided
Growth
2026 full year
-1.5% – 1.5%

Quarter detail

How the reported period landed and where the business moved.

Capital returned

Dividend / share
$0.60
Full-screen source Call document